Why AbbVie Just Spent $10.9B on Apogee

AbbVie agreed to acquire Apogee Therapeutics for $10.9B, adding late-stage IL-13 and TSLP assets targeting atopic dermatitis and asthma

23 Jun 2026

On June 22, AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in cash, adding two precision biologics to its immunology pipeline. The announcement came just a day before this report, and the agreement is already confirmed as definitive.

At the center of the deal is zumilokibart, a late-stage antibody targeting IL-13 for atopic dermatitis. Alongside it sits APG273, a dual IL-13 and TSLP therapy aimed at asthma. Both candidates push AbbVie beyond its dermatology stronghold into respiratory immunology.

The timing is deliberate. Humira, AbbVie's flagship drug, continues to face biosimilar competition, and the company needs a next wave of assets to sustain revenue. CEO Robert A. Michael described the acquisition as a natural extension of AbbVie's long-term strategy, saying the company has "led and shaped the field of immunology bringing the science, scale and expertise needed to address some of the most complex diseases."

Competition in both atopic dermatitis and asthma is intensifying. Several large pharma players are already advancing targeted biologics, and Apogee's focus on highly specific IL-13 and TSLP pathways reflects a broader clinical shift toward precision mechanisms that produce better patient outcomes. Specialty pharmacy and managed care sectors should expect new options entering late-stage development sooner than anticipated.

Backed by AbbVie's capital and commercial infrastructure, Apogee's programs are positioned for faster trial progression and earlier commercialization. For patients with limited treatment options, that acceleration may matter most.